
Please try another search
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Tomas Kiselak | 38 | 2020 | Independent Director |
Jason R. Nunn | 55 | 2024 | Independent Director |
Patricia L. Allen | 63 | 2024 | Independent Director |
James Patrick Boylan | 57 | 2022 | Independent Director |
John Jacob Orloff | 68 | 2022 | Independent Director |
Leon Oliver Moulder | 68 | 2020 | CEO & Chairman of the Board |
Hongbo Lu | 53 | 2022 | Independent Director |
Patrick Gerald Enright | 64 | 2022 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review